Akari Therapeutics (AKTX) Return on Capital Employed (2015 - 2026)
Akari Therapeutics recorded quarterly Return on Capital Employed of 107.4% in Q1 2026, down 113.14% quarter-over-quarter from 50.39% in Q4 2025, and up 31429.0% year-over-year from N/an in Q1 2025.
Akari Therapeutics' Return on Capital Employed history runs 8 years deep, the most recent figure standing at 107.4% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 31429.0% year-over-year to 107.4%; the TTM figure through Mar 2026 stood at 107.4% (up 31429.0% YoY), while the FY2025 annual figure was 46.85%, up 23987.0% from the prior year.
- Return on Capital Employed came in at 107.4% for Q1 2026 at Akari Therapeutics, down from 50.39% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 659.1% in Q1 2024 to a low of 1904.88% in Q4 2024.
- A 3-year average of 194.45% and a median of 107.4% in 2026 frame the typical range for Return on Capital Employed.
- On a YoY basis, Return on Capital Employed climbed as much as 185449 bps in 2025 and fell as far as 108078 bps in 2025.
- Akari Therapeutics' Return on Capital Employed stood at 1904.88% in 2024, then surged by 97 bps to 50.39% in 2025, then plunged by 113 bps to 107.4% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 107.4%, 50.39%, and 386.9% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -21.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -107.40% |
| Dec 31, 2025 | -50.39% |
| Sep 30, 2025 | -386.90% |
| Jun 30, 2025 | -359.67% |
| Mar 31, 2025 | -421.68% |
| Dec 31, 2024 | -1,904.88% |
| Sep 30, 2024 | 388.47% |
| Jun 30, 2024 | 433.26% |
| Mar 31, 2024 | 659.10% |
| Dec 31, 2019 | 495.52% |
| Dec 31, 2018 | -0.10% |
| Sep 30, 2018 | -331.04% |
| Jun 30, 2018 | -264.32% |
| Mar 31, 2018 | -0.11% |
| Dec 31, 2017 | -0.12% |
| Sep 30, 2017 | -190.01% |
| Jun 30, 2017 | -125.32% |
| Mar 31, 2017 | -0.09% |
| Dec 31, 2016 | -0.08% |
| Sep 30, 2016 | -49.42% |
| Jun 30, 2016 | -90.04% |
| Mar 31, 2016 | -0.07% |
| Dec 31, 2015 | -0.07% |
| Sep 30, 2015 | -837.78% |
| Jun 30, 2015 | -160.16% |
| Mar 31, 2015 | -180.18% |